In a significant move for medtech innovation, Creo Medical has successfully raised £11 million through a new share placement, securing support from major institutional investors.
- The fundraise aims to enhance Creo Medical’s growth, focusing on developing technology in minimally invasive surgical endoscopy for cancer care.
- An additional £5 million is targeted via a retail offering, underlining the firm’s commitment to expanding its financial base.
- A strategic sale of a 51% stake in Creo Europe to Micro-Tech is expected to bolster resources, bringing in an estimated £25.2 million.
- Despite revenue challenges, Creo Medical’s leadership remains optimistic, backed by investor confidence and strategic partnerships.
In a landmark financial achievement, Creo Medical, headquartered in Chepstow, successfully raised £11 million by placing new shares with key institutional shareholders. This substantial capital injection serves to support advancements in their medical technologies, particularly focusing on minimally invasive surgical endoscopy aimed at pre-cancer and cancer treatment.
Eager to further boost their financial resources, the company plans to raise an additional £5 million through a retail offer. This step highlights their robust strategy in sustaining long-term growth and development, securing their leadership in pioneering medical solutions.
In a strategic manoeuvre to enhance financial standing, Creo Medical is set to sell a 51% stake in Creo Europe to China’s Micro-Tech, a leader in endoscopic devices with annual sales of approximately £250 million. The deal, pending regulatory approval, is expected to finalise in the early part of next year, potentially generating £25.2 million in proceeds.
According to Craig Gulliford, the chief executive of Creo, the proceeds from the fundraising are crucial for accelerating the firm’s technological innovation. In his words, it will help “maximise the growth opportunities with strategic partners, driving core products and revenues.” This sentiment underscores the trust and backing from the shareholder community.
Despite reporting a decline in revenues from £15.7 million to £15.2 million in the first half of 2024 and an increase in Ebitda losses, Creo Medical remains resolute in its mission. Broker Cavendish’s analysis projects Creo to achieve Ebitda positivity by 2028, indicating a promising outlook for the company’s financial and operational pursuits.
Creo Medical’s recent financial activities reflect strategic foresight and optimism, positioning the company for innovative growth in medical technology.
